Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as 
Introduction
The metabolic activation of a compound to form reactive metabolites (RMs) that undergo covalent binding (CB) to cellular macromolecules is considered to be an undesirable property for a drug (Kaplowitz, 2005; Baillie, 2006; Uetrecht, 2007) . Current hypotheses based on retrospective studies suggest that metabolism to form RMs is an initial step in many drug-induced adverse events, such as direct damage to target organs or immune-mediated toxicity, that are involved in idiosyncratic drug toxicity (IDT). IDT occurs in rare cases and is generally manifested as severe hepatotoxicity, agranulocytosis, or other illnesses (Uetrecht, 2001 ). Many pharmaceutical companies now perform an assay for CB to assess the risk of a compound producing an adverse event (Uetrecht, 2001; Evans et al., 2004; Obach et al., 2008; Bauman et al., 2009; Nakayama et al., 2009; Usui et al., 2009; Reese et al., 2010; Thompson et al., 2010) .
The current gold-standard approach for reliable quantification of the extent to which RMs covalently bind to proteins is the CB assay using radiolabeled compounds. However, during the process of lead optimization, the CB assay, because of its low throughput and high costs, is unsuitable for assessing whether lead compounds are liable to undergo bioactivation. Pharmaceutical companies have therefore made considerable efforts to develop alternative methods with higher throughputs. Trapping methods using [
35 S]GSH, K 14 CN, or the fluorescent dansylate analog of GSH have been established for semiquantitative assessment of the bioactivation potential of compounds (Evans et al., 2004; Inoue et al., 2009; Kumar et al., 2009; Tang and Lu, 2010) . Several reports have shown the existence of a positive correlation between the extent of CB and the rate of adduct formation of the trapping agent. For example, Takakusa et al. (2009) demonstrated a good correlation of CB within a single series of derivatives by using [
35 S]GSH as the trapping agent. Meneses-Lorente et al. (2006) obtained a similar result for piperidine-containing compounds by using K 14 CN. However, trapping methods alone cannot replace the CB assay, because methods that use nucleophiles can only detect RMs that have the opportunity to diffuse into the incubation medium from the active site of the enzyme. We hypothesized that mechanism-based inhibition (MBI), which is caused by the binding of short-lived RMs to the active site of the enzymes and is detected in time-dependent inhibition (TDI) assays, could be complementary to trapping methods. There are some reports regarding TDI and the extent of CB. For example, bergamottin is a mechanism-based inhibitor of the enzymes CYP3A4, 1A2, 2B6, 2C9, and 2C19. When 14 C-labeled bergamottin was incubated with membrane preparations of individual human recombinant cytochrome P450 (P450) enzymes, the extent of CB correlated well with the inhibitory potentials of these enzymes (Kumar et al., 2009 ). On the basis of this result, a TDI assay might be capable of detecting RMs and might provide a surrogate method for the overall assessment of bioactivation potential in advance of preparing labeled compounds for a CB assay.
In this study, we investigated the relationships between the formation rate of [
35 S]GSH adducts, the enzyme inactivation rate in the TDI assay, and the extent of CB in human liver microsomes (HLMs) for 42 structurally diverse marketed compounds to clarify whether the incorporation of TDI assays would result in improved accuracy in detection of RMs.
Materials and Methods

Materials.
A total of 42 radiolabeled compounds were used. Amodiaquine, benzbromarone, carbamazepine, clozapine, clopidogrel, donepezil, flutamide, furosemide, imipramine, nevirapine, olanzapine, pioglitazone, rosiglitazone, sulfamethoxazole, tienilic acid, tacrine, valsartan, zafirlukast, and zomepirac (all 14 C labeled) were obtained from BlyChem Ltd. (Billingham, UK). Levofloxacin, olmesartan, pravastatin, and ticlopidine (all 14 C labeled) were obtained from Sekisui Medical Co., Ltd. (Ibaraki, Japan).
14 C-labeled atorvastatin was obtained from MDS Pharma Services (Montreal, QC, Canada). Celecoxib and warfarin (both 14 C labeled) and propranolol and tamoxifen (both 3 H labeled) were purchased from GE Healthcare (Chalfont St. Giles, UK). Acetaminophen, aminopyrine, caffeine, diclofenac, erythromycin, procainamide, and valproic acid (all 14 C labeled) and ethinylestradiol and fluoxetine (both 3 H labeled) were purchased from American Radiolabeled Chemicals (St. Louis, MO). Indomethacin and phenytoin (both 14 C labeled) and 3 H-labeled verapamil were purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA).
14 C-labeled amlodipine and 3 H-labeled ritonavir were purchased from Moravek Biochemicals (Brea, CA). The specific activities of 14 C-labeled compounds were in the range 13 to 58 mCi/mmol.
3 H-labeled compounds were diluted with their unlabeled compounds to give a final specific activity of 200 mCi/mmol. Unlabeled acetaminophen, amodiaquine, benzbromarone, carbamazepine, clozapine, diclofenac, erythromycin, ethinylestradiol, fluoxetine, flutamide, furosemide, imipramine, indomethacin, phenytoin, propranolol, sulfamethoxazole, tacrine, tamoxifen, ticlopidine, verapamil, warfarin, and zomepirac were obtained from Sigma-Aldrich (St. Louis, MO). Unlabeled aminopyrine, amlodipine, and valproic acid were purchased from Wako Pure Chemicals (Osaka, Japan). Unlabeled nevirapine, olanzapine, and ritonavir were purchased from Toronto Research Chemicals Inc. (North York, ON, Canada). Unlabeled caffeine and zafirlukast were obtained from Fluka (Buchs, Switzerland) and Cayman Chemical (Ann Arbor, MI), respectively. Unlabeled atorvastatin, celecoxib, clopidogrel, donepezil, levofloxacin, olmesartan, pioglitazone, pravastatin, procainamide, rosiglitazone, tienilic acid, and valsartan were synthesized by Daiichi Sankyo Co., Ltd. (Tokyo, Japan). Pooled HLMs (n ϭ 50, mixed gender) were purchased from XenoTech, LLC (Lenexa, KS). [
35 S]GSH was purchased from PerkinElmer Life and Analytical Sciences (Buchs, Switzerland). Phenacetin was purchased from Wako Pure Chemicals. Acetaminophen, paclitaxel, tolbutamide, dextromethorphan, and dextrorphan were purchased from Sigma-Aldrich. Midazolam was purchased from Ultrafine Chemicals (Manchester, UK). Bupropion, hydroxytolbutamide, (S)-mephenytoin, (Ϯ)-4Ј-hydroxymephenytoin, and 1Ј-hydroxymidazolam were purchased from BD Gentest (Franklin Lakes, NJ). (Ϯ)-Hydroxybupropion was purchased from Toronto Research Chemicals Inc.
␤-NADP
ϩ and glucose-6-phosphate dehydrogenase (G6PDH) were purchased from Oriental Yeast Co., Ltd. (Tokyo, Japan), and glucose 6-phosphate (G6P) was obtained from Sigma-Aldrich. All other reagents and solvents were of the highest grade commercially available.
CB Assay Using HLMs. The experimental procedure was based on that used in previously reported studies (Evans et al., 2004; Masubuchi et al., 2007) . The experiments were performed in triplicate. The incubation mixture consisted of the following: 10 M radiolabeled test compound (substrate), 2 mg/ml HLMs, 0.1 M potassium phosphate buffer (pH 7.4), 25 mM G6P, 2 units/ml G6PDH, and 10 mM MgCl 2 . The mixture was preincubated for 3 min at 37°C. Reaction was initiated by the addition of ␤-NADP ϩ to reach a final concentration of 2.5 mM, and the final incubation volume was 0.5 ml. As the substrates were dissolved in acetonitrile, the final incubation mixture contained 1% v/v acetonitrile. Radiolabeled compounds of at least 95% purity were used. After incubation of the mixture for 1 h, the reaction was terminated by the addition of ice-cold acetonitrile (0.5 ml). The mixture was then vortexed, sonicated in an ultrasonic bath, and centrifuged. The precipitated protein was washed twice with each of the following solvents in sequence: 80% (v/v) aqueous methanol containing 10% (w/v) trichloroacetic acid, diethyl ethermethanol (1:1, v/v), and 80% aqueous methanol. The resulting precipitated protein was dissolved in 0.5 ml of 1.0 M NaOH. Aliquots were taken for protein assay with a DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA) and also for the determination of radioactivity by using a liquid scintillation counter after mixing the aliquot with a Hionic-Fluor scintillation cocktail (PerkinElmer Life and Analytical Sciences, Wellesley, MA). The amount of the test drug-related material as radioactivity covalently bound to the microsomal protein was calculated as a measure of the extent of CB (in picomoles per milligram protein).
[ 35 S]GSH Trapping Assay. The experimental procedure was based on that used in a previously reported study . Each test compound was dissolved in acetonitrile-methanol (9:1, v/v) or acetonitrile-water (1:1, v/v) to prepare a 10 mM stock solution. Each test compound (100 M) was then incubated at 37°C with HLMs (2 mg/ml protein) and an NADPHgenerating system in 0.1 M potassium phosphate buffer (pH 7.4) supplemented with [
35 S]GSH (0.2 mM, 925 kBq/test). The final reaction mixture contained 25 mM G6P, 2 units/ml G6PDH, and 10 mM MgCl 2 . Reaction was initiated by the addition of ␤-NADP ϩ to reach a final concentration of 2.5 mM after a 3-min preincubation at 37°C. The final incubation volume was 0.5 ml. A sample containing a vehicle solution (9:1 acetonitrile-methanol or 1:1 acetonitrile-water) without substrate was used as a negative control. After a 30-min incubation, the reaction was terminated by the addition of ice-cold acetonitrile (0.5 ml). The sample was centrifuged at 2000g for 15 min at 4°C, and the supernatant was concentrated to approximately 0.1 ml by using a centrifuge evaporator. The concentrated sample (50 l) was analyzed by radio-highperformance liquid chromatography (HPLC) using an LC-10Avp HPLC system (Shimadzu, Kyoto, Japan) with an online radioactivity detector (␤-RAM model 3; IN/US Systems, Tampa, FL). The HPLC system was equipped with a 4.6 mm i.d. ϫ 150 mm (5 m) column (TSKgel ODS-100V; TOSOH, Tokyo, Japan) coupled with a 3.2 ϫ 15 mm (5 m) guard column (TSKguardgel ODS-100V; TOSOH). The sample was separated by using linear-gradient conditions at a flow rate of 1 ml/min. Ecoscint Flow (National Diagnostics, Atlanta, GA) was used as the scintillation fluid cocktail at a flow rate of 1 ml/min. ) ϭ Area GS / Area total ϫ the total amount of GSH (pmol)/the reaction time (min)/the amount of HLMs protein (mg protein).
The total amount of GSH was 100,000 pmol, the reaction time was 30 min, and the amount of HLM protein was 1 mg of protein. Area total (counts) expresses the total radioactivity counts observed on the radiochromatogram, calculated by means of the following equation: Area total ϭ radioactivity injected (dpm) ϫ f (counts/dpm).
The correction constant f (counts/dpm) was calculated by dividing the total radioactivity counts observed on the radiochromatogram of a 1:20 diluted sample by its radioactivity (disintegrations per minute). A liquid scintillation counter (TRI-CARB 2900TR; PerkinElmer Life and Analytical Sciences) was used to measure the radioactivity (disintegrations per minute) of the sample. The lower limit of quantification in each assay was set at the value of the formation rate of [
35 S]GSH adducts of diclofenac, which was obtained from each assay.
TDI Assay. The experimental procedure was based on that used in a previously reported study (Watanabe et al., 2007) . The TDI assay was automated by using a Beckman Biomek FX (Beckman Coulter, Fullerton, CA). The preincubation solution contained 0.5 mg/ml (for CYP3A4), 1.0 mg/ml (for CYP1A2, 2B6, 2C8, 2C9, and 2D6), or 2.0 mg/ml (for CYP2C19) HLMs. The probe substrate and their final concentration were as follows: 50 M phenacetin for CYP1A2, 50 M bupropion for CYP2B6, 10 M paclitaxel for CYP2C8, 200 M tolbutamide for CYP2C9, 50 M (S)-mephenytoin for CYP2C19, 30 M dextromethorphan for CYP2D6, or 2.5 M midazolam for CYP3A4. The preincubation and incubation solutions contained 0.1 M sodium phosphate buffer. The preincubation solution (178 l) was transferred into the wells of the assay plate, and 2 l of a test compound solution or control solution (10% v/v dimethyl sulfoxide) was added. The concentration of each test compound was initially set at 100 M. When the reversible inhibition of the compound was strong (percentage of control (0 min) Ͻ 50%), it was diluted to a suitable concentration, as listed in Table 1 . The preincubation reactions were initiated by the addition of 20 l of an NADPH-generating system consisting of 25 mM ␤-NADP ϩ , 250 mM G6P, 20 units/ml G6PDH, and 100 (Masubuchi et al., 2007) ; TDI (Jean et al., 1996) 
GSH (Masubuchi et al., 2007) ; TDI (Watanabe et al., 2007 Calculation of the Enzyme Inactivation Rate. The percentage of enzyme inactivation was transformed into the enzyme inactivation rate by correcting for the incubation time and the contents of each isoform. The following equation was used to calculate the enzyme inactivation rate in each of the tested P450 isoforms: enzyme inactivation rate (nmol ⅐ min Ϫ1 ⅐ mg protein Ϫ1 ) ϭ percentage of enzyme inactivation ϫ contents of each isoform (nmol/mg protein)/preincubation time (min).
The values for the contents of each isoform were taken from Simcyp version 8.0 (Simcyp Ltd., Sheffield, UK) as follows (in pmol/mg protein): 52 CYP1A2, 17 CYP2B6, 24 CYP2C8, 73 CYP2C9, 14 CYP2C19, 8 CYP2D6, and 142 CYP3A4. The preincubation time was 30 min. The sum of the rates of inactivation of all the tested P450 isoforms was calculated. Compounds that showed a percentage of enzyme inactivation of more than 10% in at least one isoform in the TDI assay were defined as positive in the TDI assay. Group 1 consisted of compounds that were judged as negative in both assays, group 2 consisted of compounds that were judged as positive in the TDI assay only, group 3 consisted of compounds that were judged as positive in the [ 35 S]GSH trapping assay only, and group 4 consisted of compounds that were judged as positive in both assays.
Calculations of the Combined Intrinsic Clearance for Forming RMs
Statistical Analysis. Statistical analyses were performed with SAS System Release 8.2 (SAS Institute, Cary, NC). Spearman rank correlation coefficients were calculated to evaluate the relationship between the rates of formation of [ 35 S]GSH adducts and the extent of CB (see Fig. 1 ), between the enzyme inactivation rates and the extent of CB (see Fig. 2) , and between the values of CL int, RMs and the extent of CB (see Fig. 3 ). In relation to the extent of CB, the Wilcoxon rank-sum test was performed for group comparison between groups 1 and 2, 1 and 3, 1 and 4, 2 and 4, and 3 and 4; a value of p Ͻ 0.05 was considered to be statistically significant (see Table 2 ).
Results
The Extent of CB in HLMs, the Formation Rate of [ 35 S]GSH Adducts, and the Percentage of Enzyme Inactivation in the TDI Assay. A summary of the extent of CB in HLMs, the formation rate of [
35 S]GSH adducts, and the percentage of enzyme inactivation in the TDI assay with the previous reports on GSH adduct formation, MBI, or TDI as references is presented in Table 1 . With the exception of levofloxacin, all the compounds showed measurable degrees of CB. The extent of CB of the tested compounds ranged from 1.4 pmol/mg protein for valsartan to 937.5 pmol/mg protein for ethinylestradiol. The extent of CB was more than 50 pmol/mg for 19 compounds. A total of 50 pmol/mg was a target maximal value for CB in selecting drug candidates for entry into development as reported by the Merck group (Evans et al., 2004 (Fig. 1) . The Spearman rank correlation coefficients (r) between the formation rate of [ 35 S]GSH adducts and the extent of the CB was calculated to be 0.50 ( p ϭ 0.0008). Four compounds (erythromycin, pioglitazone, ritonavir, and tacrine) that showed an extent of CB of more than 50 pmol/mg protein did not show detectable [
S]GSH adduct peaks.
Relationship between the Enzyme Inactivation Rate in the TDI Assay and the Extent of CB in HLMs. To consider the enzyme inactivation for all the tested P450 isoforms together, the percentage of enzyme inactivation was corrected for the incubation time and the contents of the isoform, and the enzyme inactivation rate was calculated. The logarithm of the extent of CB was plotted against the logarithm of the sum of each enzyme inactivation rate (Fig. 2) . Erythromycin, pioglitazone, ritonavir, and tacrine, which did not show a detectable [ 35 S]GSH adduct peak (Fig. 1) , did inactivate the P450 enzyme. However, the extent of CB was not correlated with the enzyme inactivation rate (r ϭ 0.14, p ϭ 0.37). Furthermore, six compounds with CB of more than 50 pmol/mg protein did not show inactivation of any of the tested P450 isoforms. (Table 1) in at least one isoform in the TDI assay were defined as TDI positive. The list of the compounds and the mean values Ϯ S.D.s, minima, and maxima in the extent of CB in each group are shown in Table 2 . Group 1 consists of 11 compounds that showed negative results in both the GSH trapping and TDI assays (Ϫ/Ϫ); similarly, group 2 (Ϫ/ϩ), group 3 (Ϯ/Ϫ), and group 4 (ϩ/ϩ) contained 10, 10, and 11 compounds, respectively. Group 1 showed a significantly lower extent of CB than did group 2 and group 3 ( p ϭ 0.001 and 0.02, respectively). Group 4 showed a significantly higher extent of CB than did group 2 ( p ϭ 0.01). Although not statistically significant ( p ϭ 0.053), the average value of the extent of CB in group 4 (353 pmol/mg protein) was higher than that of group 3 (104 pmol/mg protein).
Relationship between the Combined Intrinsic Clearance for Forming RMs and the Extent of CB. The CL int, RMs were calculated based on the formation rates of [ 35 S]GSH adducts and P450 enzyme inactivation rates (Table 3 ). The logarithm of the extent of CB was plotted against the CL int, RMs (Fig. 3) . The Spearman rank correlation coefficient was 0.77 ( p Ͻ 0.0001).
Discussion
In a previous study, we established a zone classification system that uses the extent of CB in human hepatocytes and the daily dose to assess the risks of IDT (Nakayama et al., 2009) . It is clear from our previous result that both the extent of the CB and the daily dose are risk factors for IDT. From a practical point of view, because the efficacious daily dose cannot be easily determined in the early stages of drug discovery, experimental approaches to minimize the risk of bioactivation should be used to minimize the risk of toxicity. However, because of its low throughput and high costs, the CB assay is unsuitable for use as a bioactivation assay during the process of lead optimization.
The [ 35 S]GSH trapping assay, which is often used to detect RMs, has the advantages that it does not require radiolabeled compounds and that it provides quantitative information on the formation of RMs. However trapping methods alone cannot replace the CB assay. We hypothesized that the TDI assay might be complementary to the [ 35 S]GSH trapping assay in detecting RMs.
First, we showed that the [ 35 S]GSH trapping assay alone failed to show good correlation with the extent of CB (Fig. 1) . Then, as expected from our hypothesis, four compounds (erythromycin, pioglitazone, ritonavir, and tacrine) that the [ 35 S]GSH trapping assay failed to detect, but which showed a high extent of CB, were inactivators of the P450 enzyme (Fig. 2) . Furthermore, there was a tendency for compounds that were judged as positive in the TDI assay to show a high degree of the extent of CB, irrespectively of the results of the [ 35 S]GSH trapping assay ( Table 2 ). As mentioned under the Introduction, a mechanism-based inactivator is not easily attenuated by trapping agents; this is probably the result of rapid CB of highly reactive species at the active site of the enzyme before they have the opportunity to diffuse away from the active site and react with the trapping agent (Silverman, 1995; Kalgutkar et al., 2007) . To combine the parameters from the [ 35 S]GSH trapping assay with those from the TDI assay, we introduced a new parameter, CL int, RMs (Table 3) . As shown in Fig. 3 , the Spearman rank correlation coefficients between CL int, RMs and the extent of CB was 0.77 ( p Ͻ 0.0001), which is a better value than that of the formation rate of [
35 S]GSH adducts. Our results show that we can assess the risk of a compound forming RMs by using a combination of [
35 S]GSH trapping and TDI assays in the early stages of drug discovery; these methods have a relatively high throughput and do not require the use of radiolabeled compounds.
CL int, RMs was calculated by assuming that each enzyme reaction is linear and that the enzyme inactivation rate is equal to the rate of formation of RMs. However, the enzyme inactivation rate is proportional at the low concentration of the inactivator, and it can be saturated at high concentrations. Furthermore, TDI not only occurs by the protein-alkylation mechanism but also by quasi-irreversible or heme alkylation (Riley et al., 2007; Hollenberg et al., 2008) . For example, the mechanism of inhibition by some of the tested compounds, such as amlodipine, erythromycin, and verapamil, is reported to be quasi-irreversible inhibition (Grimm et al., 2009) . RMs that And some type of RMs generated in the incubations are not either bound to the P450 enzyme responsible for their formation (causing TDI) or are trapped by GSH. For example, GSH cannot trap some types of "hard" RMs, such as iminium ions, radical species, or aldehydes (Kumar et al., 2008 (Kumar et al., , 2009 (tacrine) or a nitroso moiety (erythromycin) (Larrey et al., 1983; Madden et al., 1993; Alvarez-Sanchez et al., 2006) . In general, these RMs could be trapped by GSH, and actually the formation of the GSH adduct of pioglitazone and tacrine using LC/MS were reported (Lim et al., 2005; Zhang and Yang, 2008) . The reason for the difference in the results seemed to be sensitivity of the detection, because the information using LC/MS is of a qualitative nature only (Kumar et al., 2009) . The RMs of pioglitazone and tacrine would be trapped using [ 35 S]GSH, but the amount of the [ 35 S]GSH adducts would be lower than the limit of quantification. On the other hand, based on the result of TDI assays, these RMs would be short-lived to the active site of the enzymes and cause TDI. Thus, we consider that most parts of the RMs of these compounds would be bound to the P450 active site, and a few RMs would diffuse away from the active site and react with the GSH.
Recently, some studies, including our own previous study, have reported that the CB of drugs in human hepatocytes shows the best correlation with their safety profiles (Bauman et al., 2009; Nakayama et al., 2009; Usui et al., 2009 ). The results of these studies showed that metabolism, which does not occur in HLMs with NADPH, is also an important factor. Examples involve the acyl glucuronides of zomepirac (Wang et al., 2001 ) and valproic acid (Kumar et al., 2000) and the ␤-oxidation of valproic acid (Baillie, 1992) . In this study, zomepirac and valproic acid were not assessed as having a positive risk of forming RMs in either the [
35 S]GSH trapping assay or the TDI assay. Therefore, it is difficult to make a complete assessment of the risk of formation of RMs by using HLMs. However, in terms of throughput and handling, HLMs provide a suitable enzyme source for the preliminary assessment of the potential risks of generating highly reactive metabolites.
In summary, we have demonstrated that a combination of the [ 35 S]GSH trapping assay and the TDI assay is an effective method for detecting compounds potentially capable of generating highly reactive metabolites in the early stages of drug discovery.
